Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12605000742673
ACTRN12605000742673
Recruiting
Phase 2

A Phase II, randomised, double-blinded, dose ranging study of AVX754 to reduce the viral load versus lamivudine in treatment experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase.

Avexa Ltd0 sites60 target enrollmentNovember 15, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Avexa Ltd
Enrollment
60
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 15, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Avexa Ltd

Eligibility Criteria

Inclusion Criteria

  • •Informed consentHIV\-1 infectedM184V mutation in reverse transcriptaseCurrently taking lamivudineViral load \>2,000 copies/mlCD4\+ T\-cell count\>50 cells.

Exclusion Criteria

  • •Hep B surface Antigen PositivePregnant or breast feeding femalesHepatitis C RNA positive requiring treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
A phase II, double blind, randomised, dose ranging, safety and efficacy trial of rapid intravenous infusion of Zoledronate versus Aredia in breast cancer patients with osteolytic metastasesBreast cancerCancer
ISRCTN29188871Cancer Research UK (CRUK) (UK)
Unknown
Phase 2
A phase 2, randomized, double-blind, dose finding study of DS-8500a in Japanese patients with type 2 diabetes mellitus
JPRN-jRCT2080223014DAIICHISANKYO Co.,Ltd.335
Active, not recruiting
Phase 1
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s Disease
CTIS2023-509613-37-01Amsterdam UMC40
Active, not recruiting
Phase 1
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT Study
EUCTR2020-001317-20-LTImcyse SA84
Active, not recruiting
Phase 1
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyType 1 DiabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2020-001317-20-BEImcyse SA84